Management of Enterocutaneous Fistula

Initial Assessment and Classification

The management of enterocutaneous fistulas requires a multidisciplinary approach with treatment tailored based on fistula location and output, with proximal or high-output fistulas requiring parenteral nutrition while distal or low-output fistulas can often be managed with enteral nutrition, as recommended by the Clinical Nutrition society 1, 2
ECFs are best classified based on output volume: low (<200 ml/day), moderate (200-500 ml/day), and high (>500 ml/day), according to the Clinical Nutrition guidelines 3
ECFs typically communicate with segments of active inflammation, often with complications including intra-abdominal abscess and luminal strictures, or with surgical anastomoses, as reported in the Gut journal 4, 5
MRI is the preferred diagnostic tool for defining fistula anatomy with highest sensitivity and specificity, as stated in the Clinical Nutrition guidelines 3

Intra-abdominal abscesses should be treated with intravenous antibiotics and radiological drainage when possible, as recommended by the Gut journal 4, 5
Surgical drainage may be required but immediate resection should be avoided, according to the Gut journal 4
Anti-TNF therapy should only be started after abscesses have been adequately treated to avoid worsening sepsis, as stated in the Clinical Nutrition guidelines 3
Immediate fluid resuscitation and electrolyte rebalancing is critical, especially for high-output fistulae, as recommended by the Clinical Nutrition society 3
Monitor and replace losses, particularly in high-output fistulae which lead to significant dehydration, according to the Clinical Nutrition guidelines 3
High-output fistulas require restriction of hypotonic/hypertonic fluids to <1000 ml daily, as stated in the Clinical Nutrition guidelines 6

Nutritional assessment and optimization is essential for all patients with ECF, as recommended by the Clinical Nutrition society 1, 2
For distal (low ileal or colonic) fistula with low output, enteral nutrition is appropriate, according to the Clinical Nutrition guidelines 1, 2
For proximal fistula and/or very high output, partial or exclusive parenteral nutrition is recommended, as stated in the Clinical Nutrition guidelines 1, 2
Surgical correction is more likely to be successful if nutritional status is optimized preoperatively, according to the Clinical Nutrition guidelines 1, 2
Be vigilant for refeeding syndrome in patients with prolonged nutritional deprivation, as recommended by the Clinical Nutrition society 2

If a fistula is associated with active inflammation (particularly in Crohn's disease), medical therapy with anti-TNF agents should be attempted, as recommended by the Gut journal 4, 5
Anti-TNF therapy has shown limited success with approximately one-third of patients achieving fistula healing, according to the Gut journal 4, 5, 3
A study of short-peptide-based enteral nutrition for three months showed successful closure of ECFs in 62.5% of Crohn's disease patients, as reported in the Clinical Nutrition journal 1, 2
Medical therapy is unlikely to help postoperative fistulae, according to the Gut journal 4, 5
High-volume fistulae usually require surgery for definitive management, as stated in the Clinical Nutrition guidelines 3
Complexity (multiple tracts) and associated stenosis reduce rates of healing with anti-TNF therapy and increase need for surgery, according to the Gut journal 4, 5
Surgery was required in 54% of patients with enterocutaneous fistulae in a retrospective series, as reported in the Gut journal 4, 5
If fistulae are associated with bowel stricture and/or abscess, surgery is strongly recommended, according to the Clinical Nutrition guidelines 3

Treatment should involve a multidisciplinary team including gastroenterologist, surgeon, and dietitian, as recommended by the Clinical Nutrition society 1, 2
Anti-TNF therapy may be more effective for inflammatory rather than postoperative fistulae, according to the Gut journal 4, 5
One-third of patients treated with anti-TNF therapy developed intra-abdominal abscess, highlighting the need for careful monitoring, as reported in the Gut journal 4, 5
Conservative approaches can be attempted but have limited success, according to the Gut journal 4, 5
Surgical intervention is often necessary but should be performed after adequate preparation, as recommended by the Gut journal 4, 5

The American Gastroenterological Association recommends that proton pump inhibitors like Prilosec (omeprazole) can reduce output in high-output enterocutaneous fistulas, particularly when there is net secretory output exceeding 3 liters per 24 hours, though they are part of a broader management strategy and will not eliminate the need for fluid/electrolyte replacement or definitive treatment 7

The European Society for Clinical Nutrition and Metabolism suggests fluid resuscitation with intravenous normal saline (2-4 liters/day) while keeping the patient nil by mouth for 24-48 hours to stop thirst-driven oral intake 7
The American Gastroenterological Association recommends correcting electrolyte abnormalities, particularly sodium and magnesium, as each liter of jejunostomy/fistula fluid contains approximately 100 mmol/L sodium 7

The American Gastroenterological Association suggests restricting oral hypotonic fluids to 500 ml/day maximum and instead sipping glucose-saline solution with sodium concentration at least 90 mmol/L 7
The European Society for Clinical Nutrition and Metabolism recommends adding antimotility agents: loperamide 2-8 mg before food, occasionally with codeine phosphate for additional reduction in output 7
The American Society for Parenteral and Enteral Nutrition suggests providing partial or exclusive parenteral nutrition rather than relying on enteral routes for proximal fistulas with very high output 8

The American Society of Colon and Rectal Surgeons recommends that high-volume fistulas usually require surgery for definitive symptom control, regardless of medical therapy 9
The European Society for Clinical Nutrition and Metabolism suggests that PPIs serve as a temporizing measure to reduce fluid/electrolyte losses during the stabilization phase and optimize nutritional status preoperatively 8
The American Gastroenterological Association recommends that low-volume enterocutaneous fistulas may be controlled with immunomodulator and biological therapy (anti-TNF agents), but medical therapy is unlikely to help postoperative fistulas 9